Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors: The relevance of dose

Journal of Affective Disorders

Volumn 135, Issue 1-3, 2011, Pages 208-215

  Roca, A ^a,b,c   Garcia Esteve, Ll ^a,d   Imaz, M L ^a   Torres, A ^a   Hernandez S ^a   Botet, F ^a,d   Gelabert, E ^b   Subira S ^b   Plaza, A ^a   Valdes M ^a,d   Martin Santos, R ^a,d,e  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Brain   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Antidepressant; Obstetrical neonatal outcomes; Pregnancy; Preterm birth; SSRI

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; CASE CONTROL STUDY; CESAREAN SECTION; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GESTATIONAL AGE; HUMAN; LABOR INDUCTION; MAJOR CLINICAL STUDY; MATERNAL AGE; MENTAL DISEASE; MOOD DISORDER; PARITY; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PRENATAL EXPOSURE; PRIORITY JOURNAL; PYELECTASIS;

ADULT; ANTIDEPRESSIVE AGENTS; CASE-CONTROL STUDIES; CESAREAN SECTION; FEMALE; FETAL MEMBRANES, PREMATURE RUPTURE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MOOD DISORDERS; PARITY; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREMATURE BIRTH; RISK; SEROTONIN UPTAKE INHIBITORS;

EID: 80055012812     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2011.07.022     Document Type: Article

References (58)

1. H.A. Bennett, A. Einarson, A. Taddio, G. Koren, and T.R. Einarson Prevalence of depression during pregnancy: systematic review Obstet. Gynecol. 103 4 2004 698 709
2. N. Boucher, A. Bairam, and L. Beaulac-Baillargeon A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy J. Clin. Psychopharmacol. 28 3 2008 334 339
3. C.D. Chambers, K.A. Johnson, L.M. Dick, R.J. Felix, and K.L. Jones Birth outcomes in pregnant women taking fluoxetine N. Engl. J. Med. 335 14 1996 1010 1015
4. K.E. Clark, E.G. Mills, T.E. Otte, and S.J. Stys Effect of serotonin on UABF in pregnant and nonpregnant sheep Life Sci. 27 1980 2655 2661
5. L.S. Cohen, V.L. Heller, J.W. Bailey, L. Grush, J.S. Ablon, and S.M. Bouffard Birth outcomes following prenatal exposure to fluoxetine Biol. Psychiatry 48 2000 996 1000
6. L.S. Cohen, B. Wang, R. Nonacs, A.C. Viguera, E.L. Lemon, and M.P. Freeman Treatment of mood disorders during pregnancy and postpartum Psychiatr. Clin. North Am. 33 2 2010 273 293
7. A.M. Costei, E. Kozer, T. Ho, S. Ito, and G. Koren Perinatal outcome following third trimester exposure to paroxetine Arch. Pediatr. Adolesc. Med. 156 11 2002 1129 1132
8. A. Einarson, J. Choi, T.R. Einarson, and G. Korenzz Adverse effects of antidepressant use in pregnancy: an evaluation of fetal growth and preterm birth Depress. Anxiety 27 1 2010 35 38
9. J. Evans, J. Heron, H. Francomb, S. Oke, and L. Golding Cohort study of depressed mood during pregnancy and after childbirth BMJ 232 2001 257 260
10. F. Figueras, E. Meler, A. Iraola, E. Eixarch, O. Coll, and J. Figueras Customized birthweight standards for a Spanish population Eur. J. Obstet. Gynecol. Reprod. Biol. 136 1 2006 20 24
11. L. Garcia-Esteve, C. Ascaso, J. Ojuel, and P. Navarro Validation of the Edinburgh Postnatal Depression Scale (EPDS) in Spanish mothers J. Affect. Disord. 75 1 2003 71 76
12. S. Gentile On categorizing gestational, birth, and neonatal complications following late pregnancy exposure to antidepressants: the prenatal antidepressant exposure syndrome CNS Spectr. 15 3 2010 167 185
13. S. Grigoriadis, and G.E. Robinson Gender issues in depression Ann. Clin. Psychiatry 19 4 2007 247 255
14. H.L. Hedriana, C.J. Munro, E.M. Eby-Wilkens, and B.L. Lasley Changes in rates of salivary estriol increases before parturition at term Am. J. Obstet. Gynecol. 184 2 2001 123 130
15. T. Heikkine, U. Elblad, and K. Laine Transplacental transfer of citalopram, fluoxetine and their primary demethylated metabolites in isolated perfused human placenta BJOG 109 9 2002 1003 1008
16. T. Heikkine, U. Ekblad, P. Palo, and K. Laine Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation Clin. Pharmacol. Ther. 73 2003 330 337
17. R.P. Heine, J.A. McGregor, T.M. Goodwin, R. Artal, R.H. Hayashi, and P.A. Robertson Serial salivary estriol to detect an increased risk of preterm birth Obstet. Gynecol. 96 4 2000 490 497
18. V. Hendrick, Z.N. Stowe, L. Altshuler, S. Hwang, E. Lee, and D. Haynes Placental passage of antidepressant medications Am. J. Psychiatry 160 5 2003 993 996
19. V. Hendrick, L.M. Smith, R. Suri, S. Hwang, D. Haynes, and L. Altshuler Birth outcomes after prenatal exposure to antidepressant medication Am. J. Obstet. Gynecol. 188 2003 812 815
20. J. Heron, T.G. O'Connor, J. Evans, J. Golding, V. Glover ALSPAC Study Team The course of anxiety and depression through pregnancy and the postpartum in a community sample J. Affect. Disord. 80 1 2004 65 73
21. A. Hostetter, Z.N. Stowe, J.R. Strader Jr., E. McLaughlin, and A. Llewellyn Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications Depress. Anxiety 11 2000 51 57
22. B. Källén Neonate characteristics after maternal use of antidepressants in late pregnancy Arch. Pediatr. Adolesc. Med. 158 2004 312 316
23. R.C. Kessler, K.A. McGonagle, M. Swartz, D.G. Blazer, and C.B. Nelson Sex and depression in the National Comorbidity Survey, I: lifetime prevalence, chronicity, and recurrence J. Affect. Disord. 29 1993 85 96
24. M.S. Kramer Late preterm birth: appreciable risks, rising incidence J. Pedriatr. 154 2 2009 159 160
25. N.A. Kulin, A. Pastuszak, S.R. Sage, B. Schick-Boschetto, G. Spivey, and M. Feldkamp Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study JAMA 279 8 1998 609 610
26. A.J. Lewis, M. Galbally, G. Opie, and A. Buist Neonatal growth outcomes at birth and one month postpartum following in utero exposure to antidepressant medication Aust. N. Z. J. Psychiatry 44 5 2010 482 487
27. A.M. Loughhead, A.D. Fisher, D.J. Newport, J.C. Ritchie, M.J. Owens, and C.L. DeVane Antidepressants in amniotic fluid: another route of fetal exposure Am. J. Psychiatry 163 1 2006 145 147
28. N. Lund, L.H. Pedersen, and T.B. Henriksen Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes Arch. Pediatr. Adolesc. Med. 163 10 2009 949 954
29. H. Malm, T. Klaukka, and P.J. Neuvonen Risks associated with selective serotonin reuptake inhibitors in pregnancy Obstet. Gynecol. 106 6 2005 1289 1296
30. S. Maschi, A. Clavenna, R. Campi, B. Schiavetti, M. Bernat, and M. Bonati Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study BJOG 115 2 2008 283 289
31. G. Mastorakos, and I. Ilias Maternal and fetal hypothalamic-pituitary- adrenal axes during pregnancy and postpartum Ann. N. Y. Acad. Sci. 997 2003 136 149 Review
32. A. Moldovan, E. Kozer, T. Ho, S. Ito, and G. Koren Perinatal outcome following third trimester exposure to paroxetine Arch. Pediatr. Adolesc. Med. 156 2002 1129 1132
33. J.L. Morrison, C. Chien, K.W. Riggs, N. Gruber, and D. Rurak Effect of maternal fluoxetine administration on uterine blood flow, fetal blood gas status, and growth Pediatr. Res. 51 4 2002 433 442
34. J.L. Morrison, K.W. Riggs, C. Chien, N. Gruber, I.C. McMillen, and D. Rurak Chronic maternal fluoxetine infusion in pregnant sheep: effects on the maternal and fetal hypothalamic-pituitary-adrenal axes Pediatr. Res. 56 1 2004 40 46
35. I. Nulman, J. Rovet, D.E. Stewart, J. Wolpin, H.A. Gardner, and J. Theis Neurodevelopment of children exposed in utero to antidepressant drugs N. Engl. J. Med. 336 4 1997 258 262
36. T.F. Oberlander, S. Misri, C.E. Fitzgerald, X. Kostaras, D. Rural, and W. Riggs Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure J. Clin. Psychiatry 65 2004 230 237
37. T.F. Oberlander, W. Warburton, S. Misri, J. Aghajanian, and C. Hertzman Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data Arch. Gen. Psychiatry 63 2006 898 906
38. T.F. Oberlander, W. Warburton, S. Misri, J. Aghajanian, and C. Hertzman Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study Br. J. Psychiatry 192 5 2008 338 343
39. Y. Okatani, K. Watanabe, Y. Nakano, and Y. Sagara Relaxant effect of nitric oxide and prostacyclin on serotonin-induced vasoconstriction of human umbilical artery Acta Obstet. Gynecol. Scand. 75 1996 108 112
40. K.H. Pearson, R.M. Nonacs, A.C. Viguera, V.L. Heller, L.F. Petrillo, and M. Brandes Birth outcomes following prenatal exposure to antidepressants J. Clin. Psychiatry 68 8 2007 1284 1289
41. M. Reis, and B. Källén Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data Psychol. Med. 40 10 2010 1723 1733
42. L.E. Ross, and L.M. McLean Anxiety disorders during pregnancy and the postpartum period: a systematic review J. Clin. Psychiatry 67 8 2006 1285 1298
43. S. Saigal, and L.W. Doyle An overview of mortality and sequelae of preterm birth from infancy to adulthood Lancet 371 9608 2008 261 269
44. C.A. Sandman, L. Glynn, C.D. Schetter, P. Wadhwa, T. Garite, and A. Chicz-DeMet Elevated maternal cortisol early in pregnancy predicts third trimester levels of placental corticotropin releasing hormone (CRH): priming the placental clock Peptides 27 6 2006 1457 1463
45. A.J. Santos-Silva, E. Cairrao, B. Marques, and I. Verde Regulation of human umbilical artery contractility by different serotonin and histamine receptors Reprod. Sci. 16 12 2009 1175 1185
46. N.R. Shah, and M.B. Bracken A systematic review and meta-analysis of prospective studies on the association between maternal cigarette smoking and preterm delivery Am. J. Obstet. Gynecol. 182 2 2000 465 472
47. G.E. Simon, M.L. Cunningham, and R.L. Davis Outcomes of prenatal antidepressant exposure Am. J. Psychiatry 159 2002 2055 2061
48. D.K. Sit, J.M. Perel, J.C. Helsel, and K.L. Wisner Changes in antidepressant metabolism and dosing across pregnancy and early postpartum J. Clin. Psychiatry 69 2008 652 658
49. C. Spielberger, R. Gorsuch, and R. Lushene STAI, Manual for the State-Trait Anxiety Inventory (Self Evaluation Questionnaire). Spanish adaptation 1982 Ed TEA Madrid
50. R. Suri, L. Altshuler, V. Hendrick, N. Rasgon, E. Lee, and J. Mintz The impact of depression and fluoxetine treatment on obstetrical outcome Arch. Womens Ment. Health 7 2004 193 200
51. R. Suri, L. Altshuler, G. Hellemann, V.K. Burt, A. Aquino, and J. Mintz Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth Am. J. Psychiatry 164 2007 1206 1213
52. R. Suri, G. Hellemann, L. Cohen, A. Aquino, and L. Altshuler Saliva estriol levels in women with and without prenatal antidepressant treatment Biol. Psychiatry 64 6 2008 533 537
53. N.M. Talge, C. Holzman, J. Wang, V. Lucia, J. Gardiner, and N. Breslau Late-preterm birth and its association with cognitive and socioemotional outcomes at 6 years of age Pediatrics 126 6 2010 1124 1131
54. S. Toh, A.A. Mitchell, C. Louik, M.M. Werler, C.D. Chambers, and S. Hernández-Díaz Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction J. Clin. Psychopharmacol. 29 6 2009 555 560
55. P.D. Wadhwa, G.L. Porto, T.J. Garite, A. Chicz-DeMet, and C.A. Sandman Maternal corticotropin-releasing hormone levels in the early third trimester predict length of gestation in human pregnancy Am. J. Obstet. Gynecol. 179 4 1998 1079 1085
56. P.D. Wadhwa, T.J. Garite, G.L. Porto, A. Chicz-DeMet, C. Dunkel-Schetter, and C.A. Sandman Placental corticotropin-releasing hormone (CRH), spontaneous preterm birth, and fetal growth restriction: a prospective investigation Am. J. Obstet. Gynecol. 191 4 2004 1063 1069
57. S.W. Wen, Q. Yang, P. Garner, W. Fraser, O. Olatunbosun, and C. Nimrod Selective serotonin reuptake inhibitors and adverse pregnancy outcomes Am. J. Obstet. Gynecol. 194 2006 961 966
58. K.L. Wisner, D.K. Sit, B.H. Hanusa, E.L. Moses-Kolko, D.L. Bogen, and D.F. Hunker Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes Am. J. Psychiatry 166 5 2009 557 566